Biomedtracker

Report Library

Pediatric Acute Leukemias (AML/ALL) KOL Interview

April 01, 2015

Highlights

Current manufacturing turnaround times for CAR-T products (2-3 weeks) for ALL are not a major limitation for pediatric leukemia patients.
CAR-T treatments may be more acutely toxic than transplant immediately after infusion, but patients may have fewer medium- and long-term complications.
Agents that target the cell cycle (CDK inhibitors, Aurora kinase inhibitors) will likely be plagued with toxicity concerns, but they are perhaps no more toxic than chemotherapy.

This KOL interview accompanies our other AML content planned for April 2015. We also plan to publish a full special report on AML Treatments and Pipelines and a special report on AML Diagnostics, in collaboration with MedDeviceTracker. For more information on MedDeviceTracker's diagnostics coverage, please visit the MedDeviceTracker website or contact your BioMedTracker sales representative.

For the full report, please download the PDF version at the top of this page.

BioMedTracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email BioMedTracker or call BioMedTracker Client Services at (858) 200-2357.

For our disclosures, please read the BioMedTracker Research Standards.

Indications Covered:

Acute Lymphoblastic Leukemia (ALL)
Acute Myelogenous Leukemia (AML)

Additional Resources: